GTG Labs (GENE): רווח נקי למניה (EPS TTM)

High regulatory barriers and patents protect the position of Genetic Technologies (GENE). Revenues are based on the sale of genomic tests for the early detection of cardiological and oncological pathologies. The annual net income per share trend demonstrates financial stability, with the indicator remaining around -1.82. Growth potential persists due to the global medical shift toward preventive diagnostics.

This metric is calculated by dividing the total annual net income by the total number of outstanding shares. This figure separates the actual intrinsic value of the business from market speculation. For Genetic Technologies (GENE), stable demand for cancer diagnostics ensures the predictability of this value. An investor can assess the resilience of this defensive healthcare asset through the company's net income per share over 12 months. This chart's price action reveals the real capitalization potential.